NCT06628791Completed
BK329 and Body Fat Reduction
Effects of Oral Intake of BK329 on Body Fat Reduction in Adults With Overweight or Obesity: a Randomized, Double-blind, Placebo-controlled Clinical Trial
Source: ClinicalTrials.gov · Last updated 6 Jan 2026
Brief summary (registry, in English)
This clinical trial aims to determine whether BK329 reduces body fat in adults with overweight or obesity and to assess its safety. The main questions are: * Does BK329 reduce body fat in participants? * What side effects occur when participants take BK329?
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 100 (actual)
- First submitted
- 4 Oct 2024
- Start date
- 26 Jan 2024
- Primary completion date
- 8 Jul 2024
- Lead sponsor
- Pusan National University Yangsan Hospital
- Diseases
- Obesity
- NCT number
- NCT06628791
What you commit to
- Study type: Interventional
- Participants enrolled: 100
- From 26 Jan 2024 to the primary completion date, 8 Jul 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Subjects with severe cerebrovascular disease (e.g., stroke, cerebral hemorrhage), heart disease (e.g., angina, myocardial infarction, heart failure, arrhythmia requiring treatment), or malignant tumors within the last 6 months. (However, subjects with a history of these diseases who are clinically stable may participate at the investigator's discretion.)
- Subjects who have taken weight-altering drugs (absorption inhibitors, appetite suppressants, obesity-related supplements, psychiatric drugs, beta-blockers, diuretics, contraceptives, steroids, or female hormones) within the last month.
- Subjects with allergies to any components of the study foods.
Lab values
- Diabetic patients with poor blood glucose control (fasting glucose ≥160mg/dL).
- Subjects with creatinine levels ≥ 2 times the upper limit of the research institution's normal range.
- Subjects with aspartate transaminase or alanine transaminase levels ≥ 3 times the upper limit of the research institution's normal range.
Other
- Uncontrolled hypertensive patients (blood pressure ≥160/100mmHg, measured after 10 minutes of rest).
- Subjects undergoing treatment for hypothyroidism or hyperthyroidism.
- Subjects experiencing severe gastrointestinal symptoms such as heartburn or indigestion (lactose intolerance).
- Subjects who have participated in commercial weight loss programs within the last 3 months.
- Subjects who have participated in or plan to participate in another clinical trial within the last month.
- Alcohol abusers.
- Subjects who quit smoking within the last 3 months.
- Pregnant or breastfeeding women or those planning pregnancy during the trial period.
- Subjects deemed inappropriate for the study by the investigator for other reasons.
Who the study is looking for
- individuals with a Body Mass Index (BMI) between 23 and 30 kg/m2.
- Individuals who have provided written consent on the consent form.
Age in the registry: 19 years to 75 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Pusan National University Yangsan Hospital Coordinator of this site? Confirm its status | Yangsan | South Korea | Unknown status |
Related publications
- Lactococcus Lactis Subsp. Lactis CAB701 Reduces Body fat mass in Adults with Overweight or Obesity: A Randomized, Double-Blind, Placebo-Controlled Trial.Probiotics Antimicrob Proteins · 2026 · PMID 42684653
This page is information, not medical advice. Discuss any trial with your doctor.